$NVLX By comparison, two independent Phase II clinical trials revealed that Nuvilex's pancreatic cancer treatment, namely the combination of tiny capsules containing live drug-activating cells together with the single cancer drug ifosfamide (used for many years to treat a variety of cancers), helped patients to a far better outcome than that previously reported with standard single-drug gemcitabine and even that reported for the just approved ABRAXANE-gemcitabine combination.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.